RESUMEN
Resumen Antecedentes El miocardio no compacto es una cardiomiopatía recientemente descrita. Su presentación a cualquier edad debuta como un síndrome de insuficiencia cardiaca, arritmias, embolismo sistémico o muerte súbita. La evidencia científica demuestra una disminución de la mortalidad en pacientes con insuficiencia cardiaca que ingresan a programas de rehabilitación cardiaca. Objetivo Evaluar el efecto de la rehabilitación cardiaca fase II en pacientes con insuficiencia cardiaca diagnosticados con miocardio no compacto. Material y métodos Se realizó un estudio observacional y retrospectivo de revisión de casos en pacientes diagnosticados con miocardio no compacto en el Servicio de Rehabilitación Cardiaca registrados hasta el año 2016. Resultados Se incluyeron cinco pacientes con edad promedio de 42 ± 10.5 años, con predominio del género femenino. Al concluir el programa de rehabilitación cardiaca fase II, los pacientes presentaron disminución de disnea, edema y plétora al 100%, p = 0.063; reducción de la presión arterial sistólica, promedio: 4.8 mmHg, p = 0.434; aumento de la frecuencia cardiaca máxima, promedio: 10 latidos por minuto, p = 0.178. No se observaron cambios en los equivalentes metabólicos (Mets) ni en el tiempo de prueba de esfuerzo. Conclusiones La rehabilitación cardiaca representa una alternativa en el manejo de la insuficiencia cardiaca secundaria a miocardio no compacto.
Abstract Background Non-compacted myocardium is a recently described cardiomyopathy. It can present itself at any age as different clinical entities, such as heart failure syndrome, arrhythmias, systemic embolism, or sudden death. Scientific evidence demonstrates a decrease in mortality in patients with heart failure who are admitted to cardiac rehabilitation programs. Objective To evaluate the effect of phase II cardiac rehabilitation programs in patients diagnosed with heart failure secondary to non-compacted myocardium. Material and methods An observational and retrospective study was performed, reviewing the cases diagnosed with non-compacted myocardium registered in the Cardiac Rehabilitation Service until 2016. Results Five patients with a mean age of 42 ± 10.5 years were included, with a female majority. At the end of the phase II cardiac rehabilitation program, all the patients presented decreased dyspnea, edema and plethora (100%, p = 0.063); a reduction in systolic blood pressure, mean: 4.8 mmHg, p = 0.434; an increase of maximum heart rate, average of 10 beats per minute, p = 0.178. No changes were observed in the Mets or in the stress test time. Conclusions Cardiac rehabilitation represents an alternative in the management of heart failure secondary to non-compacted myocardium.
RESUMEN
Platelet-derived Growth Factors (GFs) are biologically active peptides that enhance tissue repair mechanisms such as angiogenesis, extracellular matrix remodeling, and cellular effects as stem cells recruitment, chemotaxis, cell proliferation, and differentiation. Platelet-rich plasma (PRP) is used in a variety of clinical applications, based on the premise that higher GF content should promote better healing. Platelet derivatives represent a promising therapeutic modality, offering opportunities for treatment of wounds, ulcers, soft-tissue injuries, and various other applications in cell therapy. PRP can be combined with cell-based therapies such as adipose-derived stem cells, regenerative cell therapy, and transfer factors therapy. This paper describes the biological background of the platelet-derived substances and their potential use in regenerative medicine.
